Strategic Manufacturing Greffex has a manufacturing partnership with FUJIFILM Diosynth Biotechnologies to produce vaccines in the United States, signaling capacity for contract manufacturing and rapid scale partnerships.

Vaccine Platform The GREVAX Universal Platform enables rapid vaccine design and production (as little as four weeks), presenting opportunities to collaborate on timeline-driven programs across multiple infectious diseases.

Global Reach Described as a multi-national privately held firm with a global reach, positioning Greffex as a potential partner for multinational sponsors seeking diverse geography approvals and supply chains.

Early Stage Pitch Revenue is in the $10–25M range with a small team (2–10 employees), suggesting high-growth potential and a focus on strategic, high-value collaborations rather than large-scale in-house deployment.

Disease Portfolio Greffex targets a wide range of pathogens (influenza, anthrax, dengue, malaria, RSV, Ebola, HPV, TB, etc.), creating numerous cross-disease partnership opportunities for joint development, trials, and manufacturing programs.